OasisLMS

• #HRS2022 YIA Competition - Clinical EP Finalists (EN-571)
• (Under-)Utilization of Anticoagulation for AF (CE-539)
• Addressing the Needs of a Diverse Arrhythmia Population (JS-460)
• Arrhythmias in the Community: Risk factors, Detection and Management (CE-544)
• Arrhythmias Related to Spirochetes, Parasites and Viruses (CE-300)
• Arriving at a Better Understanding of COVID-19 and Arrhythmias (CE-541)
• Best of Heart Rhythm Case Reports (CE-585) Best of Heart Rhythm O2 (CE-726)
• Board Review for EP Fellows: SVT and VT (CE-314)
• Can Genetics Help After a Young Sudden Cardiac Death? (JS-193)
• Cardio-oncology: New Cancer Therapeutics and Arrhythmias (CE-299)
• Challenges and Updates in Arrhythmic Mitral Valve Prolapse Syndrome (CE-326)
• Challenging Cases for the Electrophysiologist (PC-578)
• Complex SVT Discrimination by Pacing Maneuvers (CE-223)
• Conduction System Pacing? LBBB Area Pacing and Beyond (JS-404)
• Controversies in Arrhythmia Management in Athletes (CE-207)
• Controversies in Atrial Fibrillation and Lifestyle Management (CE-286)
• Cutting Edge Advances and Challenges in Managing Patients with Arrhythmogenic Cardiomyopathy (JS-453)
• Debate: Pill in the Pocket DOAC Guided By Long-Term Continuous Monitoring as a Strategy For Stroke Prevention in AF Patients: Myth or a Possibility (CE-487)
• Debate: What is the Role of LAA Occlusion for Stroke Prevention in Atrial Fibrillation? (CE-303)
• Does Sex Matter? (CE-507)
• Early AF Treatment: Prime Time or Hold the Horses (JS-445)
• Epicardial Mapping and Ablation in 2022 - State of the Art (JS-458)
• Genotype-First Arrhythmia Risk Prediction for Arrhythmogenic Cardiomyopathy (ACM) - What Have We Achieved and Where are We Going? (JS-174)
• Getting an Eye on the Target Before the Ablation of SVT (CE-542)
• Global Arrhythmia Education and Continuous Quality Improvement (CQI) - It Takes a Planet, not a Village (JS-452)
• Heart Rhythm Journal Presents: New Advances in Managing Cardiac Arrhythmias (CE-584)
• How to Conquer the Difficult Procedure (CE-315)
• How to Optimize Care for AF Patients in the Preablation Period (JS-451)
• Inside Out: The Left Ventricle (CE-310)
• Introduction of the New HRS Expert Consensus Statement on the Management of Arrhythmias During Pregnancy: A Case-Based Discussion of Recommendations (CE-342)
• Investigation of Decedents with Sudden Unexplained Death and Patients with Sudden Cardiac Arrest and of Their Families (JS-285)
• Late-Breaking Clinical Trials: Clinical Innovations (LB-734)
• Left Atrial Appendage Occlusion: Trials and Tribulations (CE-538)
• Localization Insights from the Electrocardiogram (JS-459)
• Looking Forward: What Ongoing Clinical Trials Could Teach Us (CA-509)
• Making Genomics Equitable for All Patients with Heritable Cardiovascular Disease (JS-146) Management of the Asymptomatic Patient with a High Burden of PVCs (CE-307)
• Managing Arrhythmic Risk: New Technologies and Techniques (CE-343)
• New trials in VT management (CE-540) New Uses for Old Drugs (CE-432)
• Novel Arrhythmia Insights and Mapping Techniques (CE-520)
• Novel Mapping Approaches for Atrial Fibrillation (CE-100)
• Opioids and Arrhythmia Risk (JS-426)
• Optimal and Personalized Management of Atrial Fibrillation (JS-434)
• Peri-TAVR Conduction Blocks: To Pace or Not to Pace (CE-302)
• Pre-Excitation . . . and: Understanding Associated Conditions (CE-486)
• Presenting the 2022 HRS Expert Consensus Statement on Evaluation and Management of Arrhythmic Risk in Neuromuscular Disorders: Development, Rationale, and Application (CE-410)
• Racial and Ethnic Disparities in Clinical Electrophysiology (CE-124)
• Radiation Safety For Eps (CE-485)
• Sex Differences in Cardiac Arrhythmias (CE-245)
• SVTs Mediated by Variant Accessory Pathways (CE-169)
• The Early the Better: Afib Detection and Stroke (CE-543)
• Translating Genetics to Optimize Arrhythmia Care (JS-338)
• Understanding and manipulating the autonomic nervous system (CE-521)
• Update on Dysautonomic Syndromes: Pacing, Neuroablation and COVID (CE-346)
• Ventricular Tachycardia Management in Arrhythmic Syndromes (CE-175)
• Ventricular Tachycardia: Prediction, Outcomes, and Treatment (CE-522)

After watching a reasonable amount of Clinical Electrophysiology (Heart Rhythm 2022), the learner should be able to:

• Identify and analyze the latest scientific advances and innovations in the field of heart rhythm disorders.
• Select appropriate, evidence-directed pharmacological and non-pharmacological therapies to achieve optimal outcomes for patients with heart rhythm disorders.
• Recognize alternative perspectives regarding areas of controversy for which scientific evidence is insufficient, controversial, inconclusive, or confusing.
• Utilize quality improvement measures, methods, and tools to foster systems-based improvements in heart rhythm care, outcome, and value.
• Analyze and improve processes related to inter-professional teams, care coordination, patient engagement, and communication to optimize the delivery of patient- and family-centered care.
• Assess the impact of regulatory and institutional policies, and societal and cultural norms, on safety, timeliness, equity (including diversity and inclusion), effectiveness, efficiency, patient-centered care, and value.
• Utilize improved communication methods to engage with patients and caregivers for increased shared decision-making in the treatment of heart rhythm disorders
• Evaluate the latest technology available for both professionals and consumers in the field of heart rhythm disorders.
• Recognize disparities in health care and describe strategies to reduce these disparities in patient care.
• Utilize shared decision-making resources in discussing monitoring and treatment of patients with heart rhythm disorders.
• Describe the latest cardiac device advisories and/or recalls and explain how to share this information with patients and caregivers.
• Explain the current and future trends in digital health that will impact the treatment of heart rhythm disorders.
• Describe best practices for managing a device clinic, an AF center, and/or a multidisciplinary electrophysiology practice.

Learning objectives specific to the session are listed at the individual session within Clinical Electrophysiology (Heart Rhythm 2022).

Accreditation Statement
The Heart Rhythm Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians AMA Designation Statement
The Heart Rhythm Society designates this internet enduring activity for a maximum of 48 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM Maintenance of Certification (MOC) Statement 

Royal College of Physicians and Surgeons of Canada MOC Recognition Statement
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Other Credit Available
A Credit Certificate (for physicians) or Certificate of Participation (for non-physicians) will be provided to individuals seeking credit from the following organizations which accept AMA PRA Category 1 Credit(s)™. Note that participants are advised to contact their certifying body for specific information regarding credit submissions:
·         American Academy of Family Physicians (AAFP) (for elective credit)
·         American Academy of Nurse Practitioners Certification Board (AANPCB)
·         American Academy of Physician Assistants (AAPA)
·         American Nurses Credentialing Center (ANCC)
·         American Osteopathic Association (AOA) (for Category 2 credit)
·         Committee on Accreditation of Continuing Medical Education (Canada)
·         European Board for Accreditation in Cardiology (EBAC)
·         European CME Credits (ECMEC)
·         German Chambers of Physicians
·         National Society of Genetic Counselors (for Category 2 credit)
·         Oman Medical Specialty Board
·         Qatar Council for Healthcare Practitioners
·         Royal College of Physicians and Surgeons of Canada (RCPSC)

Disclosure Policy

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.

Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.

ACCME Definition:

*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Examples of such organizations include:

• Advertising, marketing, or communication firms whose clients are ineligible companies
• Bio-medical startups that have begun a governmental regulatory approval process
• Compounding pharmacies that manufacture proprietary compounds
• Device manufacturers or distributors
• Diagnostic labs that sell proprietary products
• Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
• Manufacturers of health-related wearable products
• Pharmaceutical companies or distributors
• Pharmacy benefit managers
• Reagent manufacturers or sellers

All relevant financial relationships have been mitigated. Individual disclosures will be shown at the session level. 
For a comprehensive list of all disclosures, please visit: https://heartrhythm.com/attend/presenter-disclosures

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company within the 24 months prior to the disclosure.

The Heart Rhythm Society takes steps to assure its learners and the public that the content of certified activities is accurate and reliable. The following principles are applied to the process of validating CME content. The content is peer-reviewed to ensure the following:

Fair Balance - that content is balanced among various options available for treatment and not biased toward a particular product or manufacturer.

Patient Treatment Recommendations - that patient treatment recommendations contained in the content are evidence-based, are appropriate for the target audience, and that the patient treatment recommendations contribute to overall improvement in patient care.

Scientific Validity - those scientific studies cited in the activity conform to standards accepted by the scientific community.

Learning Objectives - that the educational content supports the learning objectives of the activity, and that the objectives stated for performance-in-practice are actionable and measurable.

Omissions - that no seminal studies, data, or best evidence are missing

ACE (formerly CME) and CoP Certificates will be awarded and available to download and print following the completion of the course and the course evaluation. Should you have any questions regarding your certificate(s), please contact CME@HRSonline.org.